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A net +1 frameshift permits synthesis of thymidine kinase from a
drug-resistant herpes simplex virus mutant
(clinical isolate/pathogenesls/latency/acyclovir/in vitro transcription-translation)
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Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115
Communicated by Bernard Fields, January 24, 1994
ABSTRACT Clinical resistance to antiviral drugs requies
that a virus evade drug therapy yet retain pathogenicity. Thy-
midine kinase (TK)-negative mutants ofherpes simplex virus are
resistant to the drug, acyclovir, but are attenuated for patho-
genicity in animal models. However, numerous cases of clinical
resistance to acyclovir have been associated with viruses that
were reported to express no TK activity. We studied an acyclo-
vir-resistant clinical mutant that contains a single-base insertion
in its tk gene, predicting the synthesis of a truncated TK
polypeptide with no TK activity. Nevertheless, the mutant
retained some TK activity and the ability to reactivate from
latent infections of mouse trigeminal ganglia. The mutant ex-
pressed both the predicted truncated polypeptide and a low level
of a polypeptide that comigrated with full-length TK on poly-
acrylamide gels and reacted with anti-TK antiserum, providing
evidence for a frameshifting mechanism. In vitro transcription
and tanslation ofmutant tkgenes, incuding constructs in which
reporter epitopes could be expressed only if frameshiffing oc-
curred, also gave rise to truncated and full-length polypeptides.
Reverse transcriptase-polymerase chain reaction analysis cou-
pled with open reading fram cloning failed to detect alterations
in tktrspts that could account for the synthesis offull-length
polypeptide. Thus, synthesis of full-length TK was due to an
unusual net +1 frmeshlft during translation, a phenomenon
hitherto confined in eukaryotic cells to certain RNA viruses and
retrotransposons. Utilization of cellular frameshifting mecha-
nisms may permit an otherwise TK-negative virus to exhibit
clinical acyclovir resistance.
Herpes simplex virus (HSV) is an important human patho-
gen, especially in patients with AIDS. A major advance in
antiviral therapy has been the use of acyclovir to treat HSV
infections, but acyclovir resistance is a problem of increasing
clinical significance in immunocompromised patients (1).
Clinical resistance implies that HSV can mutate to evade
drug therapy yet retain pathogenicity. Because the sensitivity
of HSV to acyclovir is due largely to the viral thymidine
kinase (TK), which activates the drug (2), HSV tk mutations
can confer acyclovir resistance (3). Indeed, there have been
numerous cases ofpatients who suffered severe HSV disease
despite acyclovir therapy and shed acyclovir-resistant vi-
ruses that were reported to express no detectable TK activity
and/or full-length TK polypeptides (4-13).
Although TK is not essential for viral replication in cell
culture, it is important for viral pathogenesis in animal
models. In particular, TK- mutants fail to reactivate from
latent infections ofmouse sensory ganglia (14-16), due to the
tk mutation (16). Thus, the association of virus that appears
TK- with severe HSV disease has been puzzling. One
possible resolution of this paradox is that the clinical isolates
expressed low levels ofTK that were not detected. There are
HSV mutants that are severely impaired for TK activity and
thus acyclovir-resistant, yet express low levels ofTK that are
sufficient for certain pathogenic phenotypes, including the
ability to reactivate (17-20).
We report here a clinical acyclovir-resistant isolate that
encodes a gene predicted to express an inactive truncatedTK
polypeptide due to a single-base insertion mutation. Despite
this, the virus retains a low level ofTK activity and the ability
to reactivate from latency and expresses both the predicted
truncated polypeptide and low levels of full-length TK poly-
peptide. We show that full-length TK expression is due to a
net +1 frameshift during translation. The results provide a
potential mechanism for clinical acyclovir resistance and
have uncovered an unusual example of frameshifting that
may have unique mechanistic features.
MATERIALS AND METHODS
Cells and Viruses. Vero cells were propagated and main-
tained as described (21). Plaque-purified HSV-1 clinical iso-
lates 294.1 and 615.9 and the tk deletion mutant dlsptk have
been described (14, 22). Mutant K5DG1 was isolated from the
wild-type laboratory strain KOS by selection with 40 ,uM
ganciclovir (C.B.C.H., unpublished results) and plaque-
purified three times. Viruses were grown and titrated as
described (23).
Plaque Autoradiography. [125I]Iododeoxycytidine plaque
autoradiography was performed as described (24), except
that a methylcellulose overlay (0.5%) was used instead of
human immune serum globulin.
Reactivation from Latency. Seven-week-old CD-1 mice
were inoculated with 2 x 106 plaque-forming units ofvirus via
the cornea as described (20). Thirty days after inoculation,
trigeminal ganglia were excised and tested for the presence of
reactivatable virus by a dissociation protocol (25), modified
as described (16).
PCR and Conventional Sequencing. Virion "mini-prep"
DNA was prepared (26). The DNA was ethanol-precipitated
and the tk gene was amplified by PCR as described (27)
except that annealing was at 600C and oligonucleotide prim-
ers corresponding to nt -220 to -203 and nt 1348 to 1327 of
the KOS tk gene (28) were used. These PCR products,
processed as described (29), or cloned plasmid DNAs were
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sequenced using Sequenase (United States Biochemical)
according to the manufacturer's instructions with the two
primers listed above and primers from the tk gene corre-
sponding to nt 29-50, 90-68, 330-350 (TK9), 451-428, 490-
509, 587-607 (TK16), 655-635 (TK5), 841-858, 1037-1018,
and 1045-1065.
Plasmids. The tkgenes of 294.1 and 615.9 were amplified by
PCR as described above using the primer corresponding to nt
-220 to -203 and a primer corresponding to nt 45,564-45,582
of the HSV-1 strain 17 sequence (30), which lie downstream
of the EcoRI site in the glycoprotein H gene. The amplified
DNAs were digested with Bgl II and EcoRI and inserted into
BamHI/EcoRI-digested pGEM-7ZF(+) (Promega) to yield
plasmids pBH15 and pBH13, respectively. The inserts were
sequenced to ensure that secondary mutations were not
present. To construct plasmids pBX1 and pBX22, we started
with pTKWT, which contains the 1.9-kbp EcoRI-Pvu II tk
fragment from KOS inserted into the EcoRI and Sma I sites
ofpGEM-3Zf(+) (Promega) and pTKN20, which contains the
Kpn I-BamHI 3.4-kbp tk fragment from KSDG1 in pGEM-
7Zf(+). Plasmid pSVTK1 was then constructed by inserting
the EcoRI-Xba I fragment from pTKWT into pSVK3 (Phar-
macia). Plasmid pSVTKN20 was constructed by inserting the
EcoRl-Xba I fragment from pTKN20 into pSVK3. Plasmids
pBX1 and pBX2 entailed the insertion of the Bgl II-Xba I
fragment from pSVTK1 and pSVTKN20, respectively, into
pBlueScript II KS(+) (Stratagene) at the BamHI and Xba I
sites. pBX22 was constructed by replacing the Sac I fragment
of pBX2 downstream of the KSDG1 mutation with that of
pBX1. Plasmid pBX15 was constructed by replacing the Sty
I-Xba I fragment of pBX1 with the Nco I-Xba I fragment
from HSVpolplasmid pDP1 (31). Sequencing confirmed that
the junction of tk and pol sequences was in-frame. The
mutant version (pBX16) of this fusion construct was con-
structed by exchanging the Sac I fragment of pBX22 into
pBX15. Plasmids pBH3 and pBH4 were constructed in
several steps. First, the fragments between the Sac I sites in
the tk gene and the vector in plasmids pBX1 and pBX22 were
deleted to yield plasmids pBSl and pBS2, respectively. The
EcoRV fragments including the 5' ends of the tk genes from
these plasmids were then replaced with a blunt-ended 1.1-kb
Sal I fragment that encodes the N-terminal portion of HSV
Pol from plasmid p911 (32) to form pBH1 and pBH2, respec-
tively. These were cut with Sac I and blunt-ended, and the
2.2-kb Pvu II fragment from p911 that encodes the C-terminal
portion of HSV Pol was inserted to yield pBH3 and pBH4,
respectively.
In Vito Transcription and Translation. In vitro transcrip-
tion and translation were performed as described (33).
Protein Analysis. Vero cells in 60-mm dishes were mock-
infected or infected at a multiplicity of 3 and incubated at
37°C. Five hours after infection, [35S]methionine (DuPont/
NEN) was added to 100 pCi/ml (1 Ci = 37 GBq). Two and
a half hours later, the medium was removed, and the mono-
layers were washed twice with phosphate-buffered saline
(PBS) and then scraped into 1 ml of PBS. The cells were
pelleted by low-speed centrifugation at 4°C and resuspended
in 1 ml of IP buffer (33). These lysates were then incubated
with rabbit preimmune sera and formalin-fixed Staphylococ-
cus A (GIBCO/BRL) overnight at 4°C and microcentrifuged.
The resulting supernatants or reticulocyte lysates were sub-jected to immunoprecipitation as described (33) using anti-
sera specifically reacting with HSV-1 TK (kindly provided by
W. C. Summers, Yale University, New Haven) or the C-ter-
minal portion of HSV-1 Pol (EX3; kindly provided by K.
Weisshart and C. Knopf, Deutsches Krebsforschungszen-
trum, Heidelberg; ref. 34). 35S-labeled polypeptides were
separated on SDS/polyacrylamide gels and visualized by
fluorography with Amplify (Amersham) by using preflashed
film. The ratio of full-length to truncated products was quan-
tified by densitometry using a Microtek scanner and normal-
ized for the number of methionine residues in each product.
Reverse Transcriptase (RT)-PCR and Open Reading Frame
Cloning. After transcription of pBX1 and pBX22, nucleic
acids were treated for 1 h at 370C with 10 units ofRNase-free
DNase I (Promega). Reaction products were phenol/
chloroform-extracted and ethanol-precipitated, and the RNA
was used as a template for cDNA synthesis with the TK5
primer and avian myeloblastosis virus RT (Promega) by
following the manufacturer's directions. One-twentieth ofthe
resulting cDNA was then diluted in PCR amplification buffer
(27) and amplified by PCR using TK9 andTK5 as described for
PCR sequencing above. The resulting PCR products were
cleaved with Rsa I and Sac I and treated with T4 DNA
polymerase in the presence of all four dNTPs to remove the
overhanging 3' ends at the Sac I site, and the relevant Rsa
I-Sac I fragment was isolated and ligated into Sma I-digested
phosphatase-treated pMR100 (ref. 35; plasmid kindly provided
by M. Gray, Tufts University, Boston). The resulting ligation
mixture was transformed into Escherichia coli JM109, plated,
and scored on MacConkey agar as described (35, 36).
RESULTS
A Clinical HSV Mutant with a tk Insertion Mutation. We
studied a clinical acyclovir-resistant tk mutant ofHSV, 615.9,
that was plaque-purified from virus isolated from a patient
who suffered severe HSV esophagitis despite acyclovir ther-
apy (22). Mutant 615.9 is genetically related to strain 294.1,
which was plaque-purified from a drug-sensitive pretreat-
ment isolate from the same patient (22). We sequenced the
615.9 and 294.1 tk genes. The only difference between the
615.9 and 294.1 tk genes was the insertion of a guanosine into
a run of seven guanosines that begins at nt 540 relative to the
transcriptional start site (37), thereby creating a run of eight
guanosines. The insertion mutation shifts the tk mRNA
sequence out of frame so that translation would be predicted
to stop at a UGA codon, yielding a truncated polypeptide of
227 aa (Fig. 1). Moreover, as the shift in frame is upstream of
residues reported to be critical for TK activity (38-40), the
predicted truncated polypeptide would be expected to lack
TK activity.
Mutant 615.9 Retains Low TK Activity. These sequencing
results were surprising because mutant 615.9 had previously
been reported to exhibit some TK activity (22). To exclude
the possibility that the TK activity was due to a low level of
TK+ virus in the 615.9 stock, we performed [125I]iododeoxy-
cytidine plaque autoradiography. This technique can distin-
guish TK+ from TK-deficient virus by the relative intensity
of labeling of plaques. Drug-sensitive TK+ strain 294.1
formed heavily labeled plaques (Fig. 2A). A tk deletion
mutant dlsptk, which is completely TK- (14), failed to form
labeled plaques (Fig. 2C). Mutant 615.9 anabolized the
nucleoside less efficiently than 294.1, but more efficiently
than dlsptk giving rise to less-intense plaques that were
nevertheless clearly labeled along their rims (Fig. 2B). Sim-
ilar intensities were observed among >200 plaques. Recon-
struction experiments (data not shown) showed that the
technique can readily detect a TK+ virus in a background of
TK-deficient virus. We conclude that mutant 615.9 consists
of a homogeneous population of virus that expresses a low
level of TK.
Mutant 615.9 Can Reactivate from Latency in Mouse
Tri eminal Ganglia. We tested the ability of mutant 615.9 to
reactivate from latency in mouse trigeminal ganglia after
corneal inoculation. In the mouse, truly TK- mutants are
completely deficient for reactivation (14-16); for example,
TK- mutant dlsactk has failed to reactivate from any of 37
ganglia (14, 16). In contrast, 615.9 reactivated from 3 of 12
ganglia upon explant and dissociation in the presence of Vero
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FIG. 1. Relevant sequences of the HSV 294 and 615.9.k genes.
For each line, the DNA sequence is presented above (starting at
residue 330 from the transcriptional start site) and the predicted
amino acid sequence is below with the normal TK reading frame in
the three-letter code and the -1 reading frame in the single-letter
code after the single guanosine insertion in mutants 615.9 and
K5DG1, which shifts translation to the -1 reading frame (vertical
arrow). A stop codon that closes this frame is shown with a star. The
locations ofprimers TK9 and TK5 (horizontal arrows) and restriction
sites Rsa I, EcoRV, and Sac I are indicated. The location of a stop
codon within the +1 frame is circled. The sequence between this
codon and the Sac I site is shaded, as a + 1 frameshift event should
begin downstream of the stop codon and the signals responsible for
frameshifting lie upstream of the Sac I site. A putative nucleoside
binding region(a 168-176) (38, 40) is indicated within a lightly
shaded box.
cells. In plaque autoradiography experiments similar to those
in Fig. 2, the reactivated viruses were indistinguishable from
the inoculated virus, 615.9 (E.P. and D.M.C., unpublished
results). The results indicate that 615.9 expresses sufficient
TK activity for reactivation from latency.
Mutant 615.9 Expresses Both Truncated and Fuil-Length
TK Polypeptides. To account for the TK activity and reacti-
vation from latency of 615.9, we hypothesized that this
mutant might synthesize active full-length TK via transla-
tional frameshifting (41, 42), thereby compensating for the
insertion mutation. We favored this possibility over other
mechanisms such as transcriptional errors because pretrans-
lational gene expression is generally highly faithful, whereas
translationalftrameshifting has many precedents (42). To
begin to examine this possibility, we immunoprecipitated
radiolabeled TK from lysates of radiolabeled 615.9-, 294.1-,
and mock-infected cells by using anti-TK antiserum (Fig. 3).
Fiv.2 TK activities of HSV strains. Vero-cell monolayers wereinfected with 50-250 plaque forming units (confirmed by crystal
violet staining) of HSV wild-type isolate 294.1 (A), mutant 615.9 (B),
orti deletion mutantdisptk (C) and analyzed by the o12511iodode-
oxycytidine plaque autoradiography.
FIG. 3. Immunoprecipitation of TK from infected cell lysates.
Vero cells were mock-infected (lane 1) orinfected with wild-type 294.1
(lane 2), mutant 615.9 (lane 3), mutant K5DG1 (lane 4), or wild-type
KOS (lane 5) and radiolabeled with [35S]methionine. Cell lysates were
prepared, immunoprecipitated with anti-TK serum, and analyzed on
an SDS/12.5% polyacrylamide gel. The positions of molecular mass
markers (lane M) are indicated on the left in kDa and the positions of
full-length and truncated TK polypeptides are on the right.
The major polypeptide immunoprecipitated from 615.9-
infected lysates corresponded in size (-25 kDa) to that
predicted from the insertion mutation (lane 3). However,
small amounts of a species that comigrated with full-length
TK were also observed (lane 3), consistent with our hypoth-
esis of translational frameshifting.
Frameshifting in Vitro. To confirm the findings in infected
cells and to test the frameshifting hypothesis further, we
sought to reconstitute frameshifting in vitro, adopting the
approach first used to examine translational frameshifting of
Rous sarcoma virus (41). We cloned the 294.1 and 615.9 tk
genes into a vector to permit in vitro transcription by bacte-
riophage SP6 RNA polymerase. We similarly cloned the tk
genes from the wild-type laboratory strain KOS and the
acyclovir-resistant mutant strain K5DG1, which arose spon-
taneously from KOS. The K5DG1 tk gene differs from the
KOS tk gene (28) by the same single-base insertion found in
615.9 (Fig. 1). The two mutant tk genes also differed from
each other at several nucleotides, as did their parental
drug-sensitive strains, demonstrating the independence of
the mutant isolates. Similar to 615.9, K5DG1 expressed small
amounts of full-length TK in infected cells (Fig. 3, lane 4).
After in vitro transcription, the resulting synthetic mRNAs
were translated in rabbit reticulocyte lysates (Fig. 4A). Plas-
mids containing the 615.9 (pBH13) or K5DG1 (pBX22) tk
gene directed the synthesis of both truncated and full-length
TK polypeptides (lanes 2 and 3), consistent with the results
from infected cells. Both the truncated and full-length poly-
peptides could be specifically immunoprecipitated with anti-
TK antiserum (data not shown). Densitometric scanning
showed that the full-length products were at -2% relative to
truncated products.
To demonstrate frameshifting more rigorously, we then
constructed plasmids pBX15 and pBX16 in which the C-ter-
minal portion of the HSV pol gene was fused in-frame to the
KOS and K5DG1 tk genes, respectively, at a Sty I site
downstream of the TGA codon that terminates the truncated
TK polypeptide translated from the mutant tkgene. Any bona
fide full-length product specified by pBX16 would thus be
recognized by anti-Pol antiserum EX3 (31), which does not
recognize pol translation products that are out-of-frame (data
not shown). As expected, the fusion protein directed by
wild-type plasmid pBX15 reacted with both anti-Pol and
anti-TK antisera (Fig. 4B, lanes 2 and 3). Mutant plasmid
pBX16 directed the synthesis ofa truncated product that was
recognized by anti-TK antiserum but not by anti-Pol antise-
rum and low levels of a full-length product that was immu-
noprecipitated by both antisera (lanes 5 and 6). These results
Microbiology: Hwang et al.
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FIG. 4. Analysis of frameshifting in vitro. (A) Transcription and
translation of tk genes. Wild-type tk plasmid pBH15 (lane 1), mutant
tk plasmids pBH13 (lane 2) and pBX22 (lane 3), wild-type construct
pBH3 (lane 4), mutant construct pBH4 (lane 5), and a water control
(lane 6) were transcribed and translated in vitro, and the products
were analyzed on an SDS/polyacrylamide gel alongside molecular
mass markers (lane M). The positions of full-length TK and Pol-
TK-Pol products are indicated with open and solid arrows, respec-
tively. (B) Synthesis of fusion proteins in rabbit reticulocyte lysates.
pBX15 and pBX16 were transcribed and translated in vitro, and the
products were fractionated directly on an SDS/polyacrylamide gel
(lanes 1 and 4) or immunoprecipitated with anti-TK antiserum (lanes
2 and 5) or anti-Pol antiserum (lanes 3 and 6) before fractionation. The
positions of molecular mass markers (lane M) are shown at the left
in kDa and the positions of full-length fusion polypeptides and
truncated polypeptides are indicated at the right.
demonstrate that frameshifting occurs during the in vitro
expression of the mutant tk gene.
Mutant tk Sequences Sufficient for Frameshifting. We
sought to define a short mutant tk sequence that could
mediate frameshifting. We reasoned that frameshifting must
occur downstream of a termination codon in the + 1 reading
frame, which lies upstream of the insertion mutation (Fig. 1).
Preliminary results (data not shown) further suggested that
frameshifting did not require sequences beyond the Sac I site
that lies just downstream of the insertion mutation (Fig. 1).
We therefore subcloned the 111-bp EcoRV-Sac I fragment
that encompasses this region (Fig. 1), which is identical in
615.9 and K5DG1, from either pBX1 or pBX22 into HSV pol
sequences to create plasmids pBH3 and pBH4, respectively.
Synthetic transcripts from these two plasmids were trans-
lated in rabbit reticulocyte lysates (Fig. 4A). The wild-type
plasmid, pBH3, directed the synthesis of full-length product
as expected (lane 4), whereas the mutant plasmid, pBH4,
directed the synthesis of a truncated product of the expected
size and a full-length product at -2% ofthe truncated product
(lane 5). The full-length polypeptide could be immunopre-
cipitated with antisera specific for the C-terminal region of
Pol (data not shown). Therefore, the signals responsible for
frameshifting are contained within the 111-bp fragment.
Failure to Detect Altered tk Transcripts. Although our
results were consistent with a translational mechanism such
as ribosomal frameshifting (41, 42) and we considered other
mechanisms less likely, nevertheless, we wished to deter-
mine whether frameshifting could have arisen from pretrans-
lational mechanisms. These would entail changes in mutant
tk transcripts by, for example, transcriptional stuttering (43)
so that the wild-type reading frame was restored. Transcripts
from mutant plasmid pBX22, which yielded -2% frameshift-
ing, or transcripts from wild-type plasmid pBX1 were iso-
lated. Primers TK5 and TK9 (Fig. 1), which lie outside of the
EcoRV-Sac I fragment that is sufficient for frameshifting,
were then used in RT-PCR. No PCR products were observed
in the absence of RT (data not shown). In a first experiment
analyzing radiolabeled RT-PCR products (data not shown),
at least 99%o of the mutant transcripts were the expected
length. However, this assay could not exclude the presence
of -1% altered transcripts.
To assay more sensitively for transcripts ofaltered size, we
digested the PCR products with Rsa I and Sac I (Fig. 1),
converted the 3' Sac I overhangs into blunt ends, and cloned
them into the Sma I site of the open reading frame cloning
vector, pMR100 (35). With this plasmid, insert DNA con-
taining 3N -1 bases and lacking termination codons in the
reading frame set by the vector will yield active f3-galacto-
sidase, permitting formation of red colonies on MacConkey
agar plates. If there were no alterations in the size of mutant
transcripts, the blunt-ended mutant Rsa I-Sac I fragment
would be expected to be 203 bp and, thus, yield red colonies.
On the other hand, an alteration in transcripts such as the
removal of one base (back to wild type) that would shift the
reading frame would yield white colonies. As expected,
plasmids containing the wild-type Rsa I-Sac I fragment
yielded white colonies. Ligation ofthe mutant Sac I fragment
yielded mostly red colonies. Of 742 colonies examined, 618
were red, indicating that there was no change in transcript
length that changed reading frame. The 124 remaining white
colonies were tested for the presence of tk inserts by colony
hybridization with 32P-labeled TK16 oligonucleotide. Only
two were positive. Plasmid DNA prepared from these two
colonies contained substantial deletions or other rearrange-
ments based on restriction enzyme analysis, which explained
the lack of f3-galactosidase activity. Thus, <0.2% of the
mutant transcripts contained alterations that could lead to
synthesis of full-length TK. As this is much less than the
frequency of frameshifting observed (2%), we infer that
changes in transcripts do not account for frameshifting; i.e.,
frameshifting occurred during translation.
DISCUSSION
Unusual Aspects of the Frameshift. The frameshift we have
detected is unusual relative to those previously described in
eukaryotic cells. Unlike other examples (for review, see ref.
42), it occurs in the expression of a protein that is not an
RNA-dependent polymerase and the protein is encoded by a
DNA virus not an RNA virus or retrotransposon. The
frameshift could be a + 1 slip, which has been described in
yeast (44), but not higher eukaryotes, or it could be a -2 slip
or larger "hop." For now, we refer to it as a net +1
frameshift.
The mechanism of frameshifting operating here may be
ribosomal frameshifting (41, 42). Our data and features of the
tk sequence suggest that such frameshiffting would occur
between a termination codon in the + 1 reading frame and the
beginning ofthe Sac I site in the mutant tkgene (Fig. 1). Recent
results support this suggestion (B.H. and D.M.C., unpub-
lished data). However, computer-aided analysis of this region
did not reveal any of the known heptanucleotide "slippery
sequences" that mediate ribosomal frameshifting (41, 42, 44,
45). Moreover, the analysis did not reveal elements known to
facilitate translational pausing, thereby permitting easier ribo-
5464 Microbiology: Hwang et al.
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somal realignment, such as termination codons, pseudoknots,
or "hungry" codons recognized by known rare tRNAs (42,44,
45). Recent work inE. coli suggests (46), however, that codons
recognized by abundant tRNAs can facilitate frameshifting if
there is sufficient competition for these tRNAs by other
codons. Perhaps, a similar mechanism aids ribosomal realign-
ment on the mutant tk mRNA.
A second possible mechanism for the translation of full-
length TK is frameshift suppression (47). There are several
examples offrameshift suppression in which a tRNA decodes
four bases rather than three (e.g., a run offour guanosines for
glycine), but such examples to date have entailed mutant
tRNAs, rather than a naturally occurring tRNA (47). It
should be interesting to determine the sequences and mech-
anisms that govern frameshifting in the mutant tk gene and
whether such frameshifting occurs during translation ofother
DNA virus or cellular genes in higher eukaryotes.
Implications for Drug Resistance and Pathogenesis. Given
the importance of TK for pathogenesis in animal models of
HSV infection, it has been paradoxical that many viruses
associated with severe herpetic disease in humans were
reported to express no detectable TK (4-13). Several ofthese
viruses, like mutant 615.9, were reported to express trun-
cated TK polypeptides and/or contain frameshift mutations
so that they would be expected to be completely TK- (7, 13,
39). As described here for 615.9, acyclovir-resistant mutants
that express rather low levels of TK can reactivate from
latency and exhibit other pathogenic phenotypes (17-20). For
several of these, it has often proven difficult to detect TK
activity by standard enzyme assays (18, 20); this has also
been true for mutant 615.9 (E.P. and D.M.C., unpublished
data). Thus, our results raise the possibility that certain
clinical isolates that have been reported to be TK- might
express low levels of TK due to frameshifting or other
mechanisms. Continued molecular analyses of such mutants
may illuminate mechanisms of clinical resistance and un-
cover interesting mechanisms of gene expression. We spec-
ulate that during the evolution of acyclovir-resistant virus in
patients with serious HSV disease, there is selection for
mutants such as 615.9 that are resistant to acyclovir yet
express low levels of TK sufficient for pathogenesis. This
may account for our having detected the unusual phenome-
non of net +1 frameshifting in mammalian cells.
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